Share on StockTwits

Cowen and Company began coverage on shares of Ocular Therapeutix (NASDAQ:OCUL) in a research note issued on Tuesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.

Shares of Ocular Therapeutix (NASDAQ:OCUL) opened at 14.33 on Tuesday. Ocular Therapeutix has a one year low of $11.90 and a one year high of $15.249. The stock’s 50-day moving average is $13.32 and its 200-day moving average is $13.32. The company’s market cap is $294.8 million.

Other equities research analysts have also recently issued reports about the stock. Analysts at Oppenheimer initiated coverage on shares of Ocular Therapeutix in a research note on Tuesday. They set an “outperform” rating and a $25.00 price target on the stock. Analysts at RBC Capital initiated coverage on shares of Ocular Therapeutix in a research note on Tuesday. They set an “outperform” rating and a $21.00 price target on the stock.

Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology.

The Fly On The Wall

Receive News & Ratings for Ocular Therapeutix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.